GlassScriptPhysician profile
Beverly D Schuler
NPI 1962799270
$3,132.34
in general payments reported to CMS, 2019-2025
46 companies · $993 in 2025
The $993 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $58.28 · 2021: $72.82 · 2022: $606 · 2023: $580 · 2024: $535 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $489.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Ucb, INC. | $334.23 | 2022-2025 | Bimzelx, Cimzia, Rystiggo |
| Janssen Biotech, INC. | $324.56 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $209.34 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $176.09 | 2019-2025 | |
| Eisai INC. | $116.27 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.69 | 2019-2024 | Ofev |
| Amgen INC. | $97.55 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $89.63 | 2019-2023 | Synthroid |
| Astellas Pharma US INC | $78.78 | 2023-2025 | Veozah |
| Pfizer INC. | $74.07 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $65.73 | 2022-2023 | Gvoke Hypopen |
| Argenx US, INC. | $64.17 | 2024-2025 | Vyvgart Hytrulo |
| Dexcom, INC. | $54.51 | 2023-2024 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $51.17 | 2022-2024 | Strensiq, Ultomiris |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Schuler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.